|
|
???tair.name??? >
???browser.page.title.author???
|
"su yy"???jsp.browse.items-by-author.description???
Showing items 1-10 of 68 (7 Page(s) Totally)
1 2 3 4 5 6 7 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2025-09-17 |
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration
|
Lin, YJ;Ou, DL;Su, YY;Hsu, CL;Hsiao, CF;Ko, BS;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Jeng, YM;Lee, WC;Chou, SC;Chen, TW;Chiu, CF;Shiuan, L, Jr.;Hsieh, CH;Lee, CC;Shen, YS;Cheng, AL;Chen, LT;Hsu, C |
| 國家衛生研究院 |
2025-09-15 |
Effects of birth order on the prevalence of allergic diseases in Taiwanese children: A 16-year study using two national databases
|
Chan, CK;Chen, CJ;Su, YY;Chen, MH;Lin, CC;Lin, YC;Hsieh, WS;Chiou, HY;Chen, PC |
| 國家衛生研究院 |
2025-07 |
Neoadjuvant immunotherapy is associated with a recurrence free survival benefit versus active surveillance in patients with resected hepatocellular cancer
|
Brunetti, L;D'Alessio, A;Fulgenzi, CAM;Yarchoan, M;Marron, T;Blanter, J;Torkpour, A;Lombardi, P;Baretti, M;Crowley, F;Hsu, C;Cortellini, A;Su, YY;Lee, PC;Eid, JR;Kaseb, A;Pinato, DJ |
| 國家衛生研究院 |
2025-07 |
5-FU+Nal-IRI vs FOLFOX/XELOX as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after gemcitabine and nab-paclitaxel (GemNab): A propensity score-matched analysis
|
Trovato, G;Rossini, D;Su, YY;Shan, YS;Chou, WC;Bagala, C;Bensi, M;Niger, M;Marchesi, S;Garattini, SK;Michelotti, A;Chiang, NJ;Pretta, A;Scartozzi, M;Vivaldi, C;Bartalini, L;Procaccio, L;Chen, LT;Tortora, G;Salvatore, L |
| 國家衛生研究院 |
2025-04-18 |
Revisiting maternal age and child health: A nationwide birth cohort study in Taiwan
|
Su, YY;Chen, CJ;Chen, MH;Lin, CC;Hsieh, WS;Chang, H;Chan, CK;Ho, WL;Chien, MM;Chen, PC |
| 國家衛生研究院 |
2025-03 |
Single-cell RNA sequencing via endoscopic ultrasound-guided fine-needle biopsy for pancreatic tumors uncovered an aggressive subclone with a poor prognosis
|
Su, YY;Lin, MY;Cheng, SM;Chang, WL;Hsu, CW;Yeh, CM;Yu, CC;Hou, YC;Huang, CJ;Liu, YS;Chao, YJ;Wang, DY;Shan, YS;Chen, LC |
| 國家衛生研究院 |
2025-01-18 |
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells
|
Wang, CA;Hou, YC;Hong, YK;Tai, YJ;Shen, CH;Hou, PC;Fu, JL;Wu, CL;Cheng, SM;Hwang, DY;Su, YY;Shan, YS;Tsai, SJ |
| 國家衛生研究院 |
2024-11 |
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: A cross-trial, patient-level analysis
|
D'Alessio, A;Stefanini, B;Blanter, J;Adegbite, B;Crowley, F;Yip, V;Slater, S;Fulgenzi, CAM;Celsa, C;Manfredi, GF;Pai, M;Goldin, RD;Ward, SC;Fiel, MI;Shu, DH;Su, YY;Cortellini, A;Baretti, M;Anders, R;Yarchoan, M;Hsu, C;Marron, TU;Pinato, DJ |
| 國家衛生研究院 |
2024-09 |
TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S-1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
|
Su, YY;Bai, LY;Huang, CJ;Chiu, CF;Wang, HT;Du, JS;Wang, HC;Chuang, S;Shih, YH;Lin, HC;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2024-08-28 |
Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab
|
Shen, YC;Liu, TH;Nicholas, A;Soyama, A;Yuan, CT;Chen, TC;Eguchi, S;Yoshizumi, T;Itoh, S;Nakamura, N;Kosaka, H;Kaibori, M;Ishii, T;Hatano, E;Ogawa, C;Naganuma, A;Kakizaki, S;Cheng, CH;Lin, PT;Su, YY;Chuang, CH;Lu, LC;Wu, CJ;Wang, HW;Rau, KM;Hsu, CH;Lin, SM;Huang, YH;Hernandez, S;Finn, RS;Kudo, M;Cheng, AL |
Showing items 1-10 of 68 (7 Page(s) Totally)
1 2 3 4 5 6 7 > >>
View [10|25|50] records per page
|
